Literature DB >> 27684511

Constrictive Bronchiolitis in Cystic Fibrosis Adolescents with Refractory Pulmonary Decline.

William T Harris1, J Todd Boyd2, Gary L McPhail3, Alan S Brody4, Rhonda D Szczesniak3,5, Leslie L Korbee6, Michael L Baker7, John P Clancy3.   

Abstract

RATIONALE: Refractory lung function decline in association with recurrent pulmonary exacerbations is a common, yet poorly explained finding in cystic fibrosis (CF). To investigate the histopathologic mechanisms of pulmonary deterioration during adolescence and early adulthood, we reviewed clinically-indicated lung biopsy specimens obtained during a period of persistent decline.
OBJECTIVES: To determine if peribronchiolar remodeling is prominent in lung biopsy specimens obtained in adolescents with CF refractory to conventional therapy.
METHODS: Six adolescents with CF (mean age, 16.2 y; mean FEV1, 52% predicted at biopsy) with significant pulmonary deterioration over 12-24 months (mean FEV1 decline of 14% predicted/year) despite aggressive intervention underwent computed tomography imaging and ultimately lung biopsy to aid clinical management. In addition to routine clinical evaluation, histopathologic investigation included staining for transforming growth factor-β (TGF-β, a genetic modifier of CF lung disease), collagen deposition (a marker of fibrosis), elastin (to evaluate for bronchiectasis), and α-smooth muscle actin (to identify myofibroblasts).
MEASUREMENTS AND MAIN RESULTS: All computed tomography scans demonstrated a mix of bronchiectasis and hyperinflation that was variable across lung regions and within patients. Lung biopsy revealed significant peribronchiolar remodeling, particularly in patients with more advanced disease, with near complete obliteration of the peribronchiolar lumen (constrictive bronchiolitis). Myofibroblast differentiation (a TGF-β-dependent process) was prominent in specimens with significant airway remodeling.
CONCLUSIONS: Constrictive bronchiolitis is widely present in the lung tissue of adolescents with CF with advanced disease and may contribute to impaired lung function that is refractory to conventional therapy (antibiotics, antiinflammatories, and mucolytics). TGF-β-dependent myofibroblast differentiation is prominent in areas of active fibrogenesis and may foster small airway remodeling in CF lung disease.

Entities:  

Keywords:  airway remodeling; constrictive bronchiolitis; cystic fibrosis; myofibroblast; transforming growth factor-β

Mesh:

Substances:

Year:  2016        PMID: 27684511      PMCID: PMC5291494          DOI: 10.1513/AnnalsATS.201412-594OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  57 in total

Review 1.  The myofibroblast in pulmonary fibrosis.

Authors:  Sem H Phan
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

2.  Pathologic aspects of bronchiolitis obliterans organizing pneumonia.

Authors:  T V Colby
Journal:  Chest       Date:  1992-07       Impact factor: 9.410

3.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

Authors:  Michael W Konstan; Wayne J Morgan; Steven M Butler; David J Pasta; Marcia L Craib; Stefanie J Silva; Dennis C Stokes; Mary Ellen B Wohl; Jeffrey S Wagener; Warren E Regelmann; Charles A Johnson
Journal:  J Pediatr       Date:  2007-06-22       Impact factor: 4.406

4.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

5.  Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction.

Authors:  Xiangwei Huang; Naiheng Yang; Vincent F Fiore; Thomas H Barker; Yi Sun; Stephan W Morris; Qiang Ding; Victor J Thannickal; Yong Zhou
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-29       Impact factor: 6.914

6.  A morphometric study of mucins and small airway plugging in cystic fibrosis.

Authors:  Pierre-Régis Burgel; David Montani; Claire Danel; Daniel J Dusser; Jay A Nadel
Journal:  Thorax       Date:  2006-08-23       Impact factor: 9.139

7.  Clinical findings and lung pathology in children with cystic fibrosis.

Authors:  Refika Hamutcu; Jon M Rowland; Monica V Horn; Cornelia Kaminsky; Eithne F MacLaughlin; Vaughn A Starnes; Marlyn S Woo
Journal:  Am J Respir Crit Care Med       Date:  2002-04-15       Impact factor: 21.405

8.  Quantitative aspects of lung pathology in cystic fibrosis.

Authors:  R E Sobonya; L M Taussig
Journal:  Am Rev Respir Dis       Date:  1986-08

Review 9.  CFTR, mucins, and mucus obstruction in cystic fibrosis.

Authors:  Silvia M Kreda; C William Davis; Mary Callaghan Rose
Journal:  Cold Spring Harb Perspect Med       Date:  2012-09-01       Impact factor: 6.915

10.  Morphometric Analysis of Explant Lungs in Cystic Fibrosis.

Authors:  Mieke Boon; Stijn E Verleden; Barbara Bosch; Elise J Lammertyn; John E McDonough; Cindy Mai; Johny Verschakelen; Mariette Kemner-van de Corput; Harm A W Tiddens; Marijke Proesmans; François L Vermeulen; Erik K Verbeken; Joel Cooper; Dirk E Van Raemdonck; Marc Decramer; Geert M Verleden; James C Hogg; Lieven J Dupont; Bart M Vanaudenaerde; Kris De Boeck
Journal:  Am J Respir Crit Care Med       Date:  2016-03-01       Impact factor: 21.405

View more
  6 in total

1.  Fibrocyte accumulation in the lungs of cystic fibrosis patients.

Authors:  Rajesh K Kasam; Prathibha R Gajjala; Anil G Jegga; Jennifer A Courtney; Scott H Randell; Elizabeth L Kramer; John P Clancy; Satish K Madala
Journal:  J Cyst Fibros       Date:  2020-06-25       Impact factor: 5.482

Review 2.  TGFβ as a therapeutic target in cystic fibrosis.

Authors:  Elizabeth L Kramer; John P Clancy
Journal:  Expert Opin Ther Targets       Date:  2017-12-13       Impact factor: 6.902

3.  Subacute TGFβ expression drives inflammation, goblet cell hyperplasia, and pulmonary function abnormalities in mice with effects dependent on CFTR function.

Authors:  Elizabeth L Kramer; William D Hardie; Satish K Madala; Cynthia Davidson; John P Clancy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-07       Impact factor: 5.464

4.  Poor recovery from cystic fibrosis pulmonary exacerbations is associated with poor long-term outcomes.

Authors:  Don B Sanders; Qianqian Zhao; Zhanhai Li; Philip M Farrell
Journal:  Pediatr Pulmonol       Date:  2017-09-07

5.  MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia.

Authors:  Farruk Lutful Kabir; Namasivayam Ambalavanan; Gang Liu; Peng Li; George M Solomon; Charitharth V Lal; Marina Mazur; Brian Halloran; Tomasz Szul; William T Gerthoffer; Steven M Rowe; William T Harris
Journal:  Am J Respir Crit Care Med       Date:  2018-03-01       Impact factor: 30.528

Review 6.  Pathophysiology of Lung Disease and Wound Repair in Cystic Fibrosis.

Authors:  Massimo Conese; Sante Di Gioia
Journal:  Pathophysiology       Date:  2021-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.